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The Burden of Disease Associated by Hypertension and Cost-
effectiveness Analysis of Adding Non-Pharmaceutical 
Interventions with Medications to Control Blood Pressure 
 
Ye Seol Lee 
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Background: Hypertension is one of the most common chronic diseases and the 
number of people suffering from it is steadily increasing in South Korea. 
Hypertension patients experience incidence of chronic disease, such as 
cardiovascular disease (“CVD”), that increase both medical and economic 
burdens. There are a variety of intervention programs that increase patient 
awareness of and control over their blood pressure to manage hypertension. 
However, no studies have compared such programs and analyzed their cost-
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effectiveness. Therefore, this study identified the burden of CVD among 
hypertensive patients and determined whether adding non-pharmaceutical 
intervention is acceptable to patients to control their blood pressure using cost-
effectiveness analysis. 
Methods: The sample population in this study was hypertensive patients at least 
30 years old. Cardiovascular disease was defined as cerebrovascular disease (I60-
69), heart failure (I50), myocardial infarction (I21-24) and chronic kidney disease 
(N18). To determine the disease burden of hypertension, the YLLs, YLDs, and 
DALYs were calculated. The incidence-based method to calculated YLDs was 
used. DALYs were used to calculate the burden of CVD caused by hypertension. 
This study examined the cost-effectiveness of non-pharmaceutical interventions 
for controlling blood pressure using a Markov model. The definitions and effects 
of the intervention program were established by citing previous studies. We 
selected self-monitoring, education, and reminder service as interventions to 
control blood pressure. The most cost-effective alternative was selected and the 
analysis was set to the limited social perspective. One-year and lifetime analysis 
periods were used in this study and QALY was an effectiveness variable. The 
costs were intervention program budgets and the medical and non-medical costs 
of hypertension and CVD. 
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Results: The incidence and mortality of CVD in hypertensive patients were the 
highest in cerebrovascular disease at the age-standardized rate (male: 29.77 
person-year/1,000 persons (incidence), 3.71 person-year/1,000 persons (mortality); 
women: 34.91 person-year/1,000 persons (incidence), 3.47 person-year/1,000 
persons (mortality)). Cerebrovascular disease DALY of hypertensive patients was 
the highest in both men and women; Male: cerebrovascular disease 345,613.88 
person-year, HF 51,200.68 person-year, MI 60,054.97 person-year, CKD 
154,978.85 person-year; Women: Cerebrovascular diseases 275,955.68 person-
year, HF 63,844.58 person-year, MI 28,474.15 person-year, CKD 106,402.20 
person-year. In this study, YLLs due to premature death were the majority of 
DALYs. In the cost-effectiveness analysis of the intervention program for blood 
pressure control, the ICER was 12,781,508 KRW when the reminder service was 
combined with the medication treatment. This has led to the same results, even 
though various uncertainty analyses have been conducted. 
Conclusion: This study showed that the burden of cerebrovascular disease among 
hypertensive patients was high and the YLLs to premature death were 
significantly high. Reminder service with medication was the most cost-effective 
methods for controlling blood pressure. In other words, it can be interpreted as 
sufficient to introduce additional reminder services to hypertensive patients. The 
results of this study can be used as a basis hypertension and CVD management 
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and prevention policy. This study faced some limitations so its results should be 
interpreted carefully and further research on the subject should be conducted. 
                                                                   
Keywords: Hypertension, Cardiovascular disease, Burden of disease, DALY, 








Hypertension is one of the most common chronic diseases in South Korea. 
There are estimated to be 11 million hypertension patients in South Korea, 
affecting 29% of people at least 30 years old1. Over 60% of the elderly population 
suffers from hypertension, a proportion which is expected to increase2. The 
quality of hypertension treatment has not kept up with the number of people 
suffering from it. Only 65% of people were aware of hypertension and only 43.7% 
of patients diagnosed with hypertension were in control of it1. These statistics 
have not changed significantly since 20072. Social and economic burdens are 
increasing along with the number of people suffering from high blood pressure. 
The average annual copayment for hypertensive patients has increased steadily 
from KRW 201,000 in 2008 to KRW 225,000 in 2011 and medication prices have 
increased from KRW 142,000 to KRW 158,000 over the same period3. Total 
medical expenses for treating hypertension among patients aged 65 and over 
increased significantly, from KRW 583.1 billion in 2005 to KRW 1,413 billion in 
20154. It is essential to manage chronic diseases such as hypertension because 
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they incur medical expenses, reduce patient quality of life, and cause premature 
death5.  
Hypertension is problematic on its own and as a cause for other diseases. The 
World Health Organization has declared that hypertension, diabetes, and obesity 
as the major leading diseases of cardiovascular disease (“CVD”) and 
recommended intensive interventions to treat them6. In 2010, Global Burden of 
Disease (“GBD”) studies in 20 countries identified high blood pressure as a risk 
factor for various chronic diseases, furthermore high blood pressure represented 
an absolute portion of Disability-Adjusted Life Years (DALYs) of chronic 
disease7,8. The rate of CVD in hypertensive patients is twice as high as in other 
patients9 and patients with hypertension and related complications have greater 
mortality rates than those with hypertension only10. Proper management of 
hypertension can reduce the risk of stroke by 35–40% and reduce the risk of 
myocardial infarction (“MI”) by 16%6. Cardiovascular disease is less likely to 
occur as a result of continuous treatment of hypertension and hypertensive 
patients with controlled blood pressure have fewer related complications than 
those without controlled blood pressure. Managing hypertension has many 
positive effects11. 
There are various methods for controlling blood pressure, the most common of 
which is through taking medications. The hypertension guideline recommends 
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that an antihypertensive medication be prescribed if the patient's systolic blood 
pressure (“SBP”) is greater than 140 mmHg12. In addition, to treat hypertension, it 
is recommended to combine lifestyle therapy (“intervention”), or lifestyle 
improvement, with medication. Intervention is not performed alone to control 
blood pressure, but serves as a secondary method for controlling blood pressure in 
hypertensive patients. For this reason, many institutions, including hospitals, aim 
to increase the effectiveness of drugs by developing interventions13-17. Several 
interventions have been developed to maximize its effectiveness. Such methods 
include educating patients and medical staff17-21; lifestyle modification programs 
to help patients control their weight22, reduce their sodium and alcohol 
consumption, and exercise more23; patient BP self-monitoring24,25; 
interdisciplinary medical teams to manage patients’ blood pressure26-28; and 
programs to increase hypertension treatment compliance and medication 
adherence29. Hypertension associations provide evidence-based strategies for 
lowering blood pressure14,16. These interventions help control blood pressure and 
hypertension and increase awareness of both conditions. Many studies have 
shown that hypertension intervention programs affect clinical indicators such as 
blood pressure, cholesterol, and the glycemic index and improve perceptions of 
hypertension, related diseases, and mental problems30-32. In South Korea, many 
efforts are being made in association with medical institutions at the national and 
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community levels to prevent and manage hypertension. In 2010, the Program for 
Prevention and Management for a Cardio-cerebrovascular Disease was released to 
improve the management of hypertension and diabetes, which are the biggest risk 
factors for cardiovascular diseases33. This plan has invigorated community health 
education and digitized clinical records for patients with hypertension and 
diabetes, improving continuity of treatment. It also provided direct economic 
incentives to vulnerable populations, such as the elderly, to seek medical 
treatment.  
However, such government action to reduce the population average blood 
pressure shows limitation to control the growing hypertension prevalence in 
Korea. As the current pilot plan for hypertension control only operates in a limited 
area, on a national level, not only the effectiveness of the treatment lacks 
convincement, but also adequate information about the health and social care 
costs34. Also, there are no practical statistics or previous studies that can measure 
the clinical burden of patients with hypertension. Therefore, using the most 
reliable big data in Korea35, this study thoroughly investigated the risk of 
hypertension related disease among hypertensive patients in Korea, and confirmed 
the consequences of additional non-pharmaceutical interventions in combination 






The purpose of this study is to determine the risk of hypertension in Korea by 
calculating the burden of CVD among hypertensive patients, and to draw 
economic evaluation of adding non-pharmaceutical interventions to 
antihypertensive medications. 
 
The objectives of this study follows:  
(1) Measure the incidence and mortality of CVD and calculate the DALY for 
each disease among hypertensive patients. 
(2) Identify costs and effectiveness of non-pharmaceutical intervention 
programs for hypertension treatment. 
(3) Conduct the cost-effectiveness analysis determined whether adding non-
pharmaceutical intervention with medications is acceptable to patients for 
hypertension treatment.  
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Ⅱ. Literature Review 
1. Burden of Disease 
 
It is difficult to set clear health standards, so morbidity and mortality are often 
used to measure a population’s health36,37. Traditionally, indicators such as 
incidence, prevalence, and fatality rates have been used to measure morbidity, and 
age-standardized mortality and average life span have been used to measure 
mortality. Recently quality of life has emerged as a popular metrics, and there is 
no longer any limit on the overall health level with indicators such as mortality 
and prevalence. For this reason, DALY and quality-adjusted life years (“QALY”) 
were developed to express population health as a single number38. 
QALY was developed to quantitatively reflect quality39. QALY is determined 
according to a patient’s mobility, pain and discomfort, ability to take care of 
themselves, levels of anxiety and depression, and the degree to which they engage 
in usual activities. So, QALY is an integrated measure of the clinical and psycho-
social burdens of a disease. 
DALY is the amount of healthy years that a person would have otherwise lived 
except for the effects of disease40,41. It was developed in the 1990s to calculate the 
loss of health due to disease and morbidity. The World Health Organization 
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(“WHO”) has studied the world’s disease burden and in 2010 founded the 
Institute for Health Metrics and Evaluation, a research institute that has taken over 
this responsibility from the WHO. It produces data to support policies intended to 
reduce the incidence of disease and prevent disease outbreaks. The burden of 
disease in South Korea was first studied in the early 2000s and has continued to be 
the subject of research since. DALY is the sum of the years of life lost (“YLL”) 
and the years lived with disability (“YLD”). There are two main methods for 
calculating YLL and YLD. One is the incidence-based method developed by the 
WHO and the other a newer method based on the prevalence of GBD. The 
WHO’s method estimates future health losses according to disease duration. 
However, due to the difficulty of measuring disease prevalence it is difficult to 
calculate the burden of disease if the prevalence rate is high but decreasing. The 
GBD’s method more accurately calculates the burden of disease by heavily 
weighting its prevalence. However, it is difficult to estimate the burden of disease 
in the future. The formula for calculating YLL is based on the same basic formula 
for both WHO and GBD studies, but the age weight and discount rate are applied 
in the WHO method. 
YLL =  𝑁 × 𝐿 
N = Number of deaths 
L = Standard of life expectancy at age of death in years (Life table) 
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The YLD has different formulas according to WHO and GBD 2010 studies and 
as follows: 
 
YLD(WHO) = 𝐼 × 𝐷𝑊 × 𝐿 
YLD(GBD 2010) = 𝑃 × 𝐷𝑊 
I = Incidence of disease 
DW = Disability weight 
L = duration of disease 
P = Prevalence of disease 
 
Research on burden of disease is being conducted around the world. In the 
study in 2010, it showed how DALY, YLL, and YLD were related to 67 risk 
factors, and the factor that is the biggest cause of disease incidence was identified 
according to region, sex, and age8. As of 2010, the major causes of the burden of 
disease were hypertension (high blood pressure), tobacco smoking including 
second-hand smoke, and household air pollution from solid fuels. The incidence 
of hypertension in 2010 was significantly higher than they were in 1990. 
Studies on the burden of disease are being conducted in South Korea, largely by 
national institutions. There have been a number of studies that have identified the 
burden of multiple diseases and the burden of diseases according to their risk 
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factors. Yun (2001) found that YLD accounted for more than 96% of the DALY 
of hypertension-related diseases for both sexes42. Lee (2015) calculated that, in 
2011, the DALY due to asthma was 155,781–488,877 person-years, equivalent to 
the death of 900–6,000 newborn babies43. Its total economic burden was KRW 
358–727 billion, 0.03–0.06% of South Korea’s GDP. Lee (2018) calculated breast 
cancer burdens according to lifestyle changes among South Korean women44. Its 
burden increases rapidly after the birth of the first child, during breastfeeding, and 
as a result of obesity and alcohol consumption. In a study of burden of disease by 
social class among the elderly, the diseases for which the elderly were the most at-
risk were hypertension, arthritis, and cancer, which accounted for about 80% of 
the total burden of disease45. The burdens of disease differed by social class. The 
elderly living alone or those in lower socio-economic groups suffered more 
inequalities in health status than others. A study that identified 117 non-
communicable disease burden showed that YLL due to the diseases decreased but 
YLD dramatically increased46. The study also showed that both population growth 





2. Intervention Programs to Manage Hypertension 
 
Chronic disease, especially hypertension, is difficult to cure and its severity is 
often dependent on lifestyle factors, so its development must be prevented through 
interventions by medical institutions, the community, and the individual. 
Hypertension management programs that are being implemented as a national 
program were reviewed. Most programs offer comprehensive programs, including 
education, counseling and reminder services, aimed at an improvement of self-
management for patients. (Table 1) 
The most common program of blood pressure control in Korean medical 
institution is education programs for hypertensive patients. These programs 
improve patient understanding of hypertension, and how hypertension is affected 
by lifestyle choices, and relevant medications. This education is a relatively easy 
form of intervention to provide. In foreign studies, we can found studies of 
various interventions unlike Korean studies. Outcome variables of these studies 
are similar to those conducted in South Korea for clinical variables such as 






Jung & Lee (2017) studied the effect of a comprehensive intervention program 
consisting of hypertension education, self-monitoring, and telephone counseling24. 
They found a statistically significant improvement in psycho-behavioral outcomes 
but not in clinical outcomes. Chang (2016) studied the effect of a chronic disease 
management education program provided by a public health center on 
hypertensive patients who were at least 60 years old19. The program’s 
effectiveness was measured in terms of self-care behaviors, quality of life, 
cholesterol levels, body weight, and waist circumference. The program educated 
recipients about exercise, stress management, and nutrition. The education 
program was shown to improve most of used variables. In this study, most of the 
clinical outcomes were significantly decreased in the hypertensive patients who 
were educated, and the knowledge of hypertension and self-care behaviors were 
also improved statistically. Jang (2014) studied the effect of an intervention 
program in which nurses visited hypertensive patients to provide them with 
comprehensive education on clinical outcomes and the patients’ self-management 
abilities47. The results showed that the effect of education provided directly by 
healthcare providers was greater than expected. Kwon, et al. (2014) studied the 
effect of education provided by healthcare providers at community healthcare 
clinics but did not find that it reduced blood pressure25. Zhu, et al. (2018)26 and 
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Okada, et al. (2017)18 found that patients who received education from nurses and 
pharmacists experienced a significant decrease in SBP.  
 
Team-based interventions 
Milani, et al. (2017) found that a team of doctors and pharmacists which 
educated patients improved their medication adherence and lifestyles48. In 
Argentina, He, et al. (2017) established the community health provider-led 
intervention program to offer for low-income patients and confirmed that the 
clinical indexes of hypertensive patients were improved27.  
 
Self-monitoring 
Stewart, et al. (2014) found that medical providers who provided medical 
information patients and checked whether they were engaging in self-monitoring 
improved medication adherence49. In the US and UK research, they studied 
patients who checked their blood pressure themselves and shared the results with 
medical providers via the internet50,51. However, McManus, et al. (2018) 
examined the monitoring intervention including whether self-monitoring itself or 
with tele-monitoring by medical staff52. All of these studies showed that the 




Due to advances in technology, in the past, patients were informed about 
treatment and medication by text messages, but now via smartphone applications. 
(“App”) However, no matter what reminder service they used, most patients were 
able to improve their medication adherence, control their blood pressure, and be 




Table 1. National program for management of hypertension in Korea 
 Program for Prevention and 
Management for a Cardio-
cerebrovascular Disease33,56 
Education center for Management 
for hypertension and diabetes33 




Patients with hypertension or 
diabetes over 30 years old 
Population over 30 years old Patients with hypertension(I10) or 
diabetes(E11) 
Organizer KCDC KCDC NHIS 
Programs Reduction in Client’s Medical 
Costs: For patents aged 65 years 
and older once a month 3,500 won 
for medical and medicine 
costs(42,000 won per year) 
Reminder Service: Remind patients 
to attend for appointments on time 
for continuous treatment, Using 
SMS (Short Message Service) or 
ACS (Auto Calling Service) 
Education and Counselling 
Support for self-management due to 
education or counselling for patients 
Establish an education center to 
visit easily for residents 
Provide an education especially for 
patients enrolled the program 
Basic course: Information about 
disease, nutrition, exercise at all-
time 
Intensive course: Information about 
disease, nutrition, exercise, 4 times 
per year (theory), over 10 times 
(practice) 
For improvement of self-
management 
Reminder service: Send a SMS to 
patients to modify their lifestyle and 
check an examination for 
complication 
Information service for health 
management 
Rental service: Rent a 
sphygmomanometer or blood 























65 years of age 
or older and 







measure their BP every 




Changes in BP, Changes in 
psycho-behavioral outcomes 
Greater improvement in self-
efficacy, self-care behavior, and 










program in public 
health center 
8 weeks Hypertension-related 
knowledge, self-care 
behavior, quality 
of life, and physiological 
parameters 
Significant difference with respect 
to the scores of hypertension-
related knowledge, self-care 
behavior, physiological 
parameters, including SBP and 












Case management of a 
home visiting health 
service 
8 weeks Biological indexes(blood 
pressure, total cholesterol, 
triglyceride, high density 
lipoprotein, low density 
lipoprotein, BMI) self-care 
abilities(knowledge/attitude 
of hypertension, management 
of medication, etc.) 
Biological indexes and self-care 
abilities were improved, except 
















2 years Blood pressure, weight, BMI 
and blood test 
Telemedicine service system was 
an effective way to deal with 








Type of intervention Period Outcomes Results 






With a diagnosis 
of hypertension; 
with uncontrolled 
BP, ≥18 years 
old, within the 
service network 






system design, decision 
support, clinical 





BP, self-care behaviors, self-
efficacy, QoL and 
satisfaction 
The blood pressure of patients in 
the study group decreased 
significantly, patients in the study 
group had significantly greater 
















more than three 
months, aged 20-
75 years 
Received brochures and 
healthy lifestyle advice 
from pharmacists using 
motivational 
interviewing methods 
during pharmacy visits  
12 
weeks 
Change in morning home 
SBP, medication changes, 
medication adherence,  
lifestyle changes, changes in 
attitudes and knowledge 
about hypertension, and 
changes in home-monitored 
BMI 
The intervention group exhibited 
a decrease in morning SBP that 
was 6.0 mmHg greater than that 
of the control group 
Team-based interventions 
Milani 














and health coaches 
participated in the 
intervention that 
included education, 
drug management, and 
lifestyle 
recommendations 
90 days The proportion of patients 
with controlled blood 
pressure, change in systolic 
blood pressure and diastolic 
blood pressure 
Mean decrease in SBP/DBP was 
14/5 mmHg in digital medicine, 
vs 4/2 mmHg in usual care.  A 
digital hypertension program is 
feasible and associated with 
significant improvement in blood 









Type of intervention Period Outcomes Results 














coaching, home BP 
monitoring, and BP 
audit and feedback), a 
physician intervention, 




The differences in SBP/DBP 
changes from baseline to the 
end of follow-up 
Experienced a greater decrease in 
SBP/DBP than did patients who 










Older than 35 
years, with blood 
pressure higher 
than 140/90 mm 
Hg, who were 
willing to self-






and usual care 
12 
months 
Clinic measured SBP at 12 
months from randomization 
Self-monitoring, with or without 
telemonitoring, leads to 

















Package comprising BP 




medication use review 
6 
months 
Change in proportion self‐
reporting medication 
adherence; BP changes 
Improved adherence to 
antihypertensive medication and 
reduced SBP 
McKinstry 














transmission of blood 
pressure readings to a 
secure website for 
review by the attending 




Mean daytime systolic 
ambulatory blood pressure 
Supported self-monitoring by 
telemonitoring is an effective 
method for achieving clinically 








Type of intervention Period Outcomes Results 
Margolis 










mmHg if having 
diabetes or CKD) 
Received home BP 
telemonitors and 




Control of SBP to less than 
140 mmHg and DBP to less 
than 90 mmHg (main 
outcome), change in BP, 
patient satisfaction, and BP 
control (secondary) 
Home BP telemonitoring and 
pharmacist case management 
achieved better BP control 















Owned and used a 
mobile smartphone, 
specifically using the 
app to promote health 




Average daily percentage 
adherence and hypertesion 
control 
The intervention with an app 
favors pharmacological 
therapeutic adherence and 
improves the percentage of 
hypertensive patient control 
Morawski 






through an online 
platform and 
mailed a home 
blood pressure 
cuff to confirm 
eligibility and to 
provide follow-
up measurements 
Using the Medisafe app, 
which includes 
reminder alerts, 
adherence reports, and 
optional peer support 
12 
weeks 
Change from baseline to 12 
weeks in self-reported 
medication adherence, 
measured by the Morisky 
medication adherence scale, 
and change in SBP 
Among individuals with poorly 
controlled hypertension, patients 
had a small improvement in self-
reported medication adherence 
but no change in SBP compared 
with controls 
Bobrow 








for high blood 
pressure  
Text messages to 
support treatment 
adherence (information 
only, interactive SMS) 
12 
months 
Change in SBP at 12 months 
from baseline 
Small reduction in SBP control 




3. Cost-Effectiveness Analysis 
 
Economic evaluations are conducted to decide between alternatives when 
resources are limited59. Analysis of the consequences of using resources in 
different ways helps to prioritize among alternatives. Such analysis can be used to 
consider how effective new treatments or drugs would be compared to existing 
treatments. 
There are four economic evaluation methods, each of which is suited for a 
different type of research59. Cost-effectiveness analysis is the most common type 
of economic evaluation used in healthcare. 
Cost-effectiveness analysis identifies the choice with the maximum effect per 
unit of cost or the minimum cost per unit of effect and is considered to be one of 
the most rational ways to distribute limited resources59,60. In healthcare, 
consequences are expressed in natural units representing health. Using QALY as 
an effectiveness parameter in cost-effectiveness analysis is a cost-utility analysis. 
Cost-utility analysis is a measure of the effectiveness of correcting of utility 
weights with complete health being 1 and death of 059,61. It is similar in 
framework to cost-effectiveness analysis, but difference is that cost-utility 
analysis uses parameters related to quality of life as measurement of consequence. 
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In addition, cost-utility analysis allows for the comparison of alternatives with 
different outcome variables while cost-effectiveness analysis does not. 
Cost-benefit analyses compare and assess individuals’ willingness to pay by 
quantifying benefits, such as improved health levels and prolonged survival, in 
terms of money rather than indicators of health itself59. Although this type of 
analysis is the most complete in economic evaluation, it is not widely used 
because its implications usually result in wealthier people having better health 
outcomes, violating a sense of equity. 
 
Table 3. Measurement of costs and consequences in economic evaluation  
Type of study Measurement/ 










Monetary units Single effect of 
interest, common to 
both alternatives, but 
achieved to different 
degrees 
Natural units 
(e.g. life-years gained, 
disability days saved, 




Monetary units Single or multiple 
effects, not necessarily 
common to both 
alternatives 
Healthy years 




Monetary units Single or multiple 
effects, not necessarily 
common to both 
alternatives 
Monetary units 
Sources: Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods 




Clinical trials and their related economic evaluations are generally not 
conducted at the same time, so models are constructed adequately to use the 
results of real situations, such as clinical trials, when making decisions59. Models 
to analyze economic evaluation can be conducted: when data sources do not 
provide enough information for analysis; to predict outcomes beyond the 
observation period; to estimate the real-world effectiveness of alternatives; and to 
apply analysis results from one environment in another environment. Cost-
effectiveness analyses are conducted by constructing a decision tree or Markov 
model for each study. 
Decision tree models are used to systematically make decisions in uncertain 
situations by analyzing the relative value of alternatives by applying probabilities 
at different stages of the decision-making process. Decision trees are suitable for 
cases in which events proceed in one direction, but Markov models are more 
appropriate for complex situations, such as chronic diseases, in which the 
exacerbation or mitigation of the disease can reoccur and the direction is 
inconsistent. Markov models are more widely used than decision tree models 
because of decision tree models’ limitations. 
Markov models are suitable for use in healthcare studies because health states 
are mutually exclusive and transitions between health conditions occurs regularly 
within a given period. Markov models can be calculated relatively simply with 
22 
 
markov chains if each transition probability is equal. Markov processes assume 
that the probabilities of transitions between health states change over time and 
assign the probability of transitions between cycles. 
Since hypertension is one of the most common chronic diseases worldwide, 
prevention and treatment methods and antihypertensive medications are being 
developed. In South Korea, cost-effectiveness analyses of hypertension education 
programs have been conducted on elderly populations patients through health 
centers. There have been many studies on the difference in awareness of 
hypertension and the economic impact of blood pressure control methods. These 
studies are used to the cost-effectiveness of particular education or other treatment 
methods. 
The main focus of analysis in South Korea is the cost-effectiveness of 
hypertension efforts and antihypertensive medications while the main focus in 





Table 4. Summary of the studies on the cost-effectiveness analysis of hypertension treatment 






Period Outcomes Results 
Paik (2012,  
Korea)62 










Society CEA Lifetime Clinical outcome 
(change of BP), 
LYG, QALY 
Low-dose combination losartan + 
amlodiping – dominated   
Combination telmisartan + amlodipine - 
ICER 53,329,932 KRW/QALY(men), 
53,317,226 KRW/QALY(women), not 
cost-effective 















vs. standard care 
Healthcare CEA 15-year Costs per QALYs 
to produce an 
ICER 
ReD CHiP care management is cost-
effective to prevent negative 
consequences of hypertension.  
African American and elderly patients 
have more favorable ICERs 














Healthcare CEA Lifetime Cost, clinical 
outcomes, QALY 
of SBP control  
Intensive treatment would be cost-
effective (51 to 79% below the WTP 
threshold of $50,000 per QALY and 76 
to 93% below the threshold of $100,000 
per QALY) 












Healthcare CEA 6-month Hypertension 





The HBPM program increased 
hypertension-related expenditures by 
$20.50 per mm Hg lowering 
of systolic BP, $1331 per additional 
patient achieving BP control at 6 














Period Outcomes Results 
Stevanović J  
et al. (2014,  
Netherlands)66 
Patients with mild 
hypertension and 
low CVD risk 
Antihypertensive 
treatment 
Healthcare CEA 10-year/ 
Lifetime 
LYGs that were 
obtained by the 
SBP-lowering 
strategy 
Larger SBP reductions were found to be 
cost-effective in both a 10-year and 
lifetime horizon. 













Healthcare CEA 1-year Health outcomes 
(change of 
SBP/DBP) 
CE ratios ranged from US$0.53-
US$0.73 per person per mmHg SBP 
decrease, and from US$0.92-US$1.42 
per person per mmHg DBP decrease;  
The community with the highest per 
capita program costs also had the best 
health outcomes 
Côté I, et al.  
(2003, 
Canada)68 
Aged between 34 







Society CBA 9 
months. 
Direct, indirect, 
and fixed costs, 
and the costs of 
pharmacist 
intervention;  
On average, exposed participants were 
willing to pay $Can0.54 per month after 
the intervention period. Benefits were 





Ⅲ. Study Methods 
1. Framework of This Study 
 
This study established two contents for measuring the burden of disease 
attributable to hypertension and evaluating of cost-effectiveness of blood pressure 
control interventions (Fig. 1). 
This study focused on hypertension as a risk factor for CVD. To calculate the 
burden of disease due to hypertension accurately, hypertensive patients were 
selected as a study population. Using incidence-based methodology, YLLs and 
YLDs of CVD were measured. The process of calculation relating to burden of 
disease is shown in Figure 1. 
The cost-effectiveness analysis of adding non-pharmaceutical intervention 
programs to medications to control blood pressure was measured using the health 
care program economic evaluation model developed by Drummond et al. (2015)59, 
which is the most widely used model for analyzing the cost-effectiveness of 
healthcare efforts. Its application to analyzing the cost-effectiveness of blood 
pressure control intervention programs is shown in Figure. 1. In this study, a 
hypothetical cohort of hypertensive patients over 30 years old was developed. The 
economic evaluation model was developed by setting blood pressure control 
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intervention programs to support antihypertensive medication treatment. The 
incidence, mortality rates, and the transition probability of hypertension-related 
complications were calculated. Then medical and non-medical costs applied to the 
model were calculated for which QALY was used as the effectiveness variable. At 
this step, the incremental cost-effective ratio was calculated and used to determine 










2. Data Sources and Study Sample 
 
This study used nationwide retrospective claims data provided by the National 
Health Insurance Service (“NHIS”). This data includes a great deal of medical 
information about people living in South Korea69.  
Estimating DALY, the target population was patients over 30 years old who 
were diagnosed with hypertension between 2007 and 2017. For the 2007 
population, 10% sampling was performed using the living area, sex, and age as 
stratification variables. 
To calculate the input variables for the cost-effectiveness analysis, we used the 
data same as that of estimating DALY, but only 2017 medical expenses and 
probabilities were used. The reason for using a single year in 2017 is that the 
analysis cycle of the CEA was set to one year. Likewise, the medical costs and 
probabilities for patients over 30 years old who visited hospitals due to 
hypertension were calculated by dividing the group by 10 years.  
In order to extract the study subjects, 1,293,176 subjects were selected as the 
baseline population, except for 116,904 patients who were diagnosed with CVD 
and 25,327 patients who died during 2007-2008.  
The ICD-10 codes for hypertension and cardiovascular diseases used to classify 











Table 5. Definition of ICD-10 code for hypertension related diseases 
Disease Definition 
Hypertension 
I10, I11, I12, I13 
* Calculating cost: Hypertension 





Basic definition * When calculating burden of disease, 
main ICD-10 codes related to CVD 
* When calculating cost-effectiveness 
analysis:  
1. Main ICD-10 codes related to CVD 
and sub-ICD-10 codes related to 
hypertension 
2. Main ICD-10 codes related to 
hypertension and sub-ICD-10 codes 
















3. Variables and Statistical Analyses 
 




This study was conducted to determine how hypertension affects the burden of 
cardiovascular disease. The most important outcome variable in calculating 
disease of burden is DALYs. YLDs and YLLs were first calculated to calculate 
DALYs. YLD is calculated using either the incidence-based method developed by 
the WHO or the prevalence-based method developed by the GBD study 
depending on the purpose of the study. In this study, using WHO method, YLDs 
were calculated based on the incidence, weighting of disability, and duration of 
disease to determine the trends of burden due to hypertension. Table 6 








DALY YLL + YLD 
 
   
YLL 
Age at death Age at death of CVD (Average) 
The NHIS 
database 
Standard of life 
expectancy 
Standard of life expectancy at age of 
death in years 
 [70]70 
Discount rate 0.03  [39]1 
Age-adjusted parameter 0.04  [39]1 
   
YLD 
Average age at onset Age at the time of cardiovascular disease 
The NHIS 
database 
Duration of disability 
Estimated disease duration, calculated by 
DISMODⅡ71,72  
Disability weight 
0.738 (cerebrovascular disease), 0.534 
(HF), 0.534 (MI), 0.594 (CKD) 
 [73]73 
Discount ratei 0.03  [39]1 
Age-adjusted parameter 0.04  [39]1 
 
  
                                                 
i Discount rate is separately applied in calculating DALY and CEA model. WHO and the 
GBD study recommended a 3% discount rate for DALY, while the HIRA recommended a 
5% discount rate for costs and effectiveness on the CEA model. 
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B. Statistical Analyses 
 
The burden of CVD among hypertensive patients was measured in three steps. 
First, YLL is based on the number of deaths and the standard life expectancy at 
the age of death and is calculated by applying the discount rate and age-weight to 
YLLs. The standard life expectancy at the age of death can generally be found in 
standard life tables used in GBD studies. In this study, the standard life 
expectancy at the age of death was conducted based on gender and the life tables 





[𝑒−(𝛾+𝛽)(𝐿+𝑎)[−(𝛾 + 𝛽)(𝐿 + 𝑎) − 1]
− 𝑒−(𝛾+𝛽)𝑎[−(𝛾 + 𝛽)𝑎 − 1]] +
1 − 𝐾
𝛾
(1 − 𝑒−𝛾𝐿) 
 
where a is age at death; L is the life expectancy at the age of death, 𝛾 is the 
discount rate, which was defined as 0.03 in this study; 𝛽 is the age-adjusted 
parameter, which was defined as 0.04 in this study; K is the modulation factor, set 




Second, we calculated YLDs. YLDs were calculated using the incidence, 
weighting of disability, and duration of disease. Patients manifest diseases in 
different ways depending on their personal characteristics, the cause of the disease, 
and the effects of the disease. To compare disease burdens, it is necessary to 
quantify conditions caused by disease using disability weighting. In this study, 
disability weighting was applied to the results of previous studies in South Korea.  
 
Table 7. Disability weight of cardiovascular diseases 
 Disability weight 
Cerebrovascular disease 0.738 
Ischemic Heart Disease† 0.534 
Chronic Kidney Disease 0.594 
† Ischemic heart disease included in heart failure and myocardial infarction 
Sources: Ministry of Health and Welfare. A Study on Measuring and Forecasting the 
Burden of Disease in Korea: Ministry of Health and Welfare; 2018. 
 
Duration of disease is the period of exposure to a disease until the patient’s 
death, but it is difficult to calculate, so it is generally estimated using Dismod II 
software71. In this study, duration was estimated using disease incidence, mortality, 




YLD = DW {
𝐾𝐶𝑒𝛾𝑎
(𝛾 + 𝛽)2
[𝑒−(𝛾+𝛽)(𝐿+𝑎)[−(𝛾 + 𝛽)(𝐿 + 𝑎) − 1]
− 𝑒−(𝛾+𝛽)𝑎[−(𝛾 + 𝛽)𝑎 − 1] +
1 − 𝐾
𝛾
(1 − 𝑒−𝛾𝐿]} 
 
where a is the average age at onset, L is the expected duration of disability, and 
DW is the disability weight. 
 
Third, the DALY of hypertension-related disease was calculated.  
 
DALY = YLD + YLL 
 





(2) Cost-Effectiveness Analysis of Intervention to Control Blood 
Pressure 
 
A. Study Model 
 
Study Population 
This study constructed a hypothetical cohort of patients over 30 years old who 
were diagnosed with hypertension. They were randomized according to the type 
of intervention they received. Changes in their SBP and the incidence of CVD 
were analyzed by Markov simulation. 
 
Analysis Perspective 
Costs were calculated from a limited social perspective. The effects of blood 
pressure control on both payers and individual patients should be considered. 
Therefore, medical and non-medical costs, such as transportation, patient’s time, 






The analysis period was lifetime (100 years old) measured in one-year cycles 
starting from the time that the patient began participating in their respective 
intervention programs to track their long-term health effects. 
 
Discount Rate 
A discount rate of 5% for both costs and effectiveness was applied according to 
the Guidelines for Economic Evaluations of Medicine74. Discount rate is 
separately applied by calculating DALY and CEA model.  
 
Intervention 
Four intervention programs (Intervention1-3, Usual care) were selected for 
analysis (Table 8). 
  
Table 8. Interventions for this study 
Intervention Contents 
Usual care Medication only 
Intervention 1 Medication and self-monitoring 
Intervention 2 Medication and patient education 
Intervention 3 Medication and reminder services 
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Interventions were defined as follows. The usual care intervention was to take 
an antihypertensive medication. There were three types of non-pharmaceutical 
interventions, each of which was in addition to taking antihypertensive medication. 
Self-monitoring was when patients used their sphygmomanometer to check their 
blood pressure daily. Patient education was when patients were provided with 
information about hypertension to improve their understanding of hypertension to 
ultimately cause them to modify their lifestyles, such as changing their eating 
habits or exercising more. Reminder services are sent clinical information and 
reminders of appointment about hospital visits or of taking medications to patients 







The following table summarizes the general description of this study. 
 
Table 9. General description of cost-effectiveness analysis 
Item Content 
Study population 
≥ 30 aged; diagnosed with hypertension and visited a hospital 
or clinic for treatment 
Excluded: patients who have had CVD before participating 
the intervention program 
Interventions 
Taking medications only  
Medications + Self-monitoring 
Medications + Patient education 
Medications + Reminder service 
Criteria the most cost-effective  
Perspective Limited-societal perspective 
Period 1-year cycle; lifetime(aged 100 years) 
Outcome QALY 
Costs 
Budget of intervention program 
Medical costs 
Non-medical costs 






The Markov model used in this study was constructed as follows. Patients over 
30 years old with hypertension were randomly assigned to the control and 
treatment groups. Hypertensive patients participated in an intervention program to 
control blood pressure. At each stage, patients were classified as having 
transitioned between health states or having maintained their current health state 
depending on the transition probability of their current health state. In this study, a 
markov process model was used in which the probability of incidence varied over 
time because the transition probabilities and costs used in this study differed by 
age. In this study, the simplest health condition was set based on previous studies 
and related epidemiological data. The condition of hypertension patients not 
having CVD were defined as healthy hypertension. Possible health statuses were 
healthy hypertension, CVD, and death. 
The one-year probabilities for incidence rates and death rates were calculated 
based on the NHIS data and transition probabilities were taken from previous 
studies. Medical costs were also calculated using the NHIS data for the one-year 
cycle and the non-medical costs were calculated using data from previous studies 
and the NHIS data. A half-cycle correction was applied because the estimates of 
transition start and end points in each cycle may have been different. SAS 9.4, 










Assumptions Using the Model 
The basic assumptions in this study were as follows: 
1. The subjects were hypertensive patients at least 30 years old did not make 
any assumptions about the duration of hypertension. 
2. In the beginning, patients are in a state of healthy hypertension and do not 
experience any other negative health conditions besides hypertension. 
3. Transition probabilities, death rates and costs differed by age. 
4. Patients participated in only one intervention program.  
5. Patients who participated in the self-monitoring program were assumed to 
purchase a sphygmomanometer every five years to check their blood 
pressure. Patients participating in the education program received 
education once per year. 




B. Input Variables 
 
Comparison of the Effect of Intervention Program Type on Blood 
Pressure 
The purpose of this study was to confirm the cost-effectiveness of intervention 
programs for controlling blood pressure. In 2010, the Cochrane Library published 
“Interventions Used to Improve Control of Blood Pressure in Patients with 
Hypertension” which analyzed the effectiveness of various intervention programs 
using the meta-analysis17. Self-monitoring, patient education, and reminder 
service were the types of chronic disease management interventions currently 
implemented in South Korea. Table 10 summarizes the effects of each 
intervention program. Each effect represents a difference in blood pressure levels 
before and after intervention. 
Table 10. Change of SBP and DBP according to intervention programs 
 Mean 95% CI 
Self-monitoring 
SBP -2.53 -3.73 – -1.34 
DBP -1.81 -2.39 – -1.23 
Education 
SBP -0.57 -1.22 – -0.08 
DBP 0.46 0.07 – 0.86 
Reminder service 
SBP -4.56 -6.31 – -2.81 
DBP -0.53 -2.01 – 0.95 
※Source: Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to 
improve control of blood pressure in patients with hypertension. The Cochrane database of 
systematic reviews. 2010(3)  
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Risk Reduction of CVD Due to Blood Pressure Lowering Effect 
The formula of CVD risk reduction presented in Glynn et al.(2002)’s study was 
used to calculate the change in blood pressure because of the intervention program, 
as a risk reduction rate for cardiovascular disease62,75. Through this, healthy 
hypertension patients were able to derive the cardiovascular disease reduction rate 
produced by each intervention program. The estimated RR was considered the 
effect of each intervention and was found by multiplying transition probability 
and death rates. 
Risk reduction in men = exp(−0.0203 × ∆SBP − 0.0282 × ∆DBP)
1
5 




The rates of risk reduction for each intervention program follows. Because 
there was no gender difference in this study, the risk reduction rates were used 
assuming the average value of both sexes. In the case of self-monitoring, 
approximately 2% of CVD risk reduction was generated through the intervention, 
1.2% through education, and 2.8% via a reminder service. 
Table 11. Risk reduction by intervention 
Intervention 
Risk reduction(%) 
Both Men Women 
Self-monitoring 0.98002 0.97973 0.98031 
Education 0.99791 1.00028 0.99553 




Health Status Transition Probability and Death Rates 
In this study, we used the transition probability from hypertension to CVD and 
the death rates of each disease as input parameters for the Markov model. The 
transition probability was the incidence rate of CVD in 2017 among hypertensive 
patients who had never previously had CVD. The death rate was defined as the 
probability of death caused by hypertension or CVD among each disease patient. 
In other words, the death rate was estimated based on the same concept as the case 
fatality of the disease. The transition probability and death rates for CVD in 
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Death rates of each disease =  
𝐷𝑒𝑎𝑡ℎ𝑠 𝑜𝑓 𝑒𝑎𝑐ℎ 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 𝑖𝑛 2017










HF MI CKD 
30-39 0.06% 0.02% 0.02% 0.02% 
40-49 0.36% 0.07% 0.09% 0.09% 
50-59 0.91% 0.12% 0.16% 0.16% 
60-69 1.58% 0.22% 0.19% 0.28% 
70-79 3.09% 0.60% 0.26% 0.54% 








HF MI CKD 
30-39 0.01% 0.28% 0.00% 0.00% 0.14% 
40-49 0.03% 0.80% 0.45% 0.40% 1.68% 
50-59 0.04% 0.72% 0.52% 0.70% 1.95% 
60-69 0.05% 0.96% 0.63% 1.03% 2.98% 
70-79 0.13% 2.03% 1.85% 3.08% 5.05% 






The effectiveness variable in this study was the QALY for each health condition 
which was checked against the results of previous studies (Table 14)76.  
 
Table 14. QALY using in this study 
Disease QALY 
Hypertension 1.00 
Cerebrovascular disease 0.65  
HF 0.64  
MI 0.70  
CKD 0.65  
※Source: Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic 






Analytical Perspective and Cost Categories 
Costs using this study were calculated by the limited social perspective, which 
is the perspective of the healthcare system, and distinguished between medical 
and non-medical costs77. Medical costs were those directly related to disease 
treatment and while non-medical costs were all other costs related to treatment, 
including transportation, the cost to caregivers, and time. 
 
Table 15. Analytical framework for costs 
Perspective Category Content 
Limited societal  
perspective 
Medical cost Cost for hypertension (Inpatient + 
Outpatient + pharmaceutical) 
Cost for CVD (Inpatient + Outpatient + 
pharmaceutical) 
Non-medical cost Transportation cost 
Patient’s time cost 
Caregiver cost 





Budget of Intervention Program 
The budget for each intervention program was as follows: 
1. Self-monitoring cost was equivalent to that of a sphygmomanometer, 
KRW 154,000, its market price at the time of the study. 
2. Patient education cost KRW 221,47461. 






The medical costs used in the model were the total medical costs per patient in 
2017. All cases in which patients visited the medical institute because of 
hypertension or CVD as the main disease were extracted from the patients’ 
medical records provided by the NHIS. Medical costs were divided by the 
inpatient/outpatient code in the medical records and were considered the total 
costs that arose when a patient visited or was admitted to the hospital, including 
treatments and examinations. All costs related to pharmaceuticals, determined by 
using the pharmaceutical-related database for each disease in a patient's medical 
records, were considered pharmacy costs. Results were calculated by age group 
(30–39, 40–49, 50–59, 60–69, 70–79, ≥80).  
51 
 
Table 16. Medical costs (Units: KRW) 
 
Age Inpatients Outpatients Pharmaceuticals Total 
Hypertension 
30-39 220,061 119,855 175,434 515,350 
40-49 159,474 124,586 176,096 460,156 
50-59 152,999 133,655 171,556 458,210 
60-69 143,300 143,487 161,978 448,765 
70-79 368,482 175,902 152,031 696,415 
≥80 1,966,482 195,918 141,764 2,304,164 
Cerebrovascular 
disease 
30-39 9,657,047  639,026  690,995  10,987,068 
40-49 14,883,615  654,076  715,953  16,253,644 
50-59 12,788,097  735,610  758,335  14,282,042 
60-69 11,987,857  772,871  823,095  13,583,823 
70-79 13,042,559  824,154  860,119  14,726,832 
≥80 15,062,278  809,141  849,296  16,720,716 
HF 
30-39 1,416,779  509,438  390,314  2,316,531 
40-49 1,791,324  594,682  453,150  2,839,156 
50-59 2,631,100  710,455  478,191  3,819,746 
60-69 1,651,064  865,630  513,238  3,029,933 
70-79 5,120,948  921,038  538,706  6,580,693 
≥80 8,891,466  868,219  546,177  10,305,863 
MI 
30-39 7,308,344  455,570  751,000  8,514,914 
40-49 7,244,839  750,054  849,938  8,844,830 
50-59 7,573,039  588,115  788,171  8,949,325 
60-69 9,771,841  669,586  781,788  11,223,215 
70-79 8,932,482  784,345  809,683  10,526,510 
≥80 13,709,682  915,614  849,434  15,474,730 
CKD 
30-39 19,770,700  12,388,629  831,908  32,991,238 
40-49 19,282,636  29,237,793  989,236  49,509,665 
50-59 13,108,946  16,611,891  769,830  30,490,667 
60-69 16,196,573  16,113,450  655,519  32,965,542 
70-79 20,137,030  15,445,027  797,694  36,379,752 






Transportation costs were defined as the round-trip costs borne by patient to get 
to healthcare centers for disease treatment. It was calculated as follows: 
 
Transportation costs per patient
= (number of inpatient admissions
× roundtrip transportation costs)
+ (number of outpatient visits
× roundtrip transportation costs) 
 
where round-trip transportation costs were assumed to be KRW 12,842 KRW for 
inpatients and KRW 10,362 for outpatients. 
Transportation costs for inpatient and outpatient visits were calculated 
according to the consumer price index which in turn was calculated based on the 
results of the National Health and Nutrition Survey(2005). The figures in this 
study were adjusted to reflect the 2017 consumer price index. Transportation costs 


















30-39 5.6  9.2  167,007  
40-49 4.8  9.8  162,488  
50-59 5.1  10.7  175,999  
60-69 5.1  11.4  183,419  
70-79 4.9  12.5  192,447  
≥80 3.6  12.8  179,950  
Cerebrovascula
r disease 
30-39 2.2  24.1  278,691  
40-49 5.6  30.9  392,785  
50-59 4.9  36.5  441,117  
60-69 5.3  41.3  496,530  
70-79 5.5  46.8  554,820  
≥80 6.9  53.0  637,902  
HF 
30-39 1.2  25.2  276,552  
40-49 4.1  30.6  370,213  
50-59 3.1  39.2  446,334  
60-69 1.5  46.4  500,294  
70-79 3.1  53.1  589,656  
≥80 5.0  55.1  635,429  
MI 
30-39 1.6  19.7  224,402  
40-49 1.0  26.1  284,161  
50-59 1.8  26.5  296,843  
60-69 1.3  29.2  318,488  
70-79 2.0  41.0  450,866  
≥80 5.2  54.9  636,703  
CKD 
30-39 5.1  74.1  834,203  
40-49 5.3  157.5  1,700,226  
50-59 5.0  97.8  1,078,543  
60-69 5.5  100.0  1,107,523  
70-79 7.5  99.5  1,127,912  




Patient’s Time Costs 
Patients’ time was defined as the time spent on receiving treatment assuming 
that patients could not engage in economically productive activities during this 
time. Measuring patients’ time spent on treatment measures lost productivity. It 
was calculated using a human capital approach by multiplying the time spent on 
medical treatments by their hourly wage. In this study, patients’ time costs were 




= number of outpatients visits
× average time spent per outpatient visit × hourly wage
× employment rate 
 
where the average time spent per outpatient visit was 1.25 hours. 
The average time spent per outpatient visit was the sum of treatment time, 
waiting time, and round-trip time, all of which were based on the Korea Medical 
Panel (2008) and the National Health Survey (2000). The employment rate was 
the official government employment rate in 2017. Wage and employment data are 




Table 18. Hourly wage and employment rate in 2017 
 Hourly wage 
(Unit: KRW) 
Employment rate 
30-39 18,280 0.753 
40-49 20,279 0.794 
50-59 18,923 0.753 
≥ 60 13,722 0.606 
Sources: NHIS. Survey report on labor conditions by employment type 2017. 2018; 




Table 19. Patient’s time costs 
 
Age 
Annual number of 
outpatients per patient 
Total time cost 
(Unit: KRW) 
Hypertension 
30-39 9.2  158,733  
40-49 9.8  198,093  
50-59 10.7  191,281  
60-69 11.4  119,614  
70-79 12.5  130,855  
≥80 12.8  134,572  
Cerebrovascular 
disease 
30-39 24.1  418,209  
40-49 30.9  627,643  
50-59 36.5  655,612  
60-69 41.3  432,786  
70-79 46.8  489,875  
≥80 53.0  555,098  
HF 
30-39 25.2  436,380  
40-49 30.6  620,622  
50-59 39.2  704,218  
60-69 46.4  485,856  
70-79 53.1  556,005  
≥80 55.1  577,096  
MI 
30-39 19.7  341,631  
40-49 26.1  529,929  
50-59 26.5  475,033  
60-69 29.2  305,450  
70-79 41.0  429,916  
≥80 54.9  575,451  
CKD 
30-39 74.1  1,285,988  
40-49 157.5  3,194,694  
50-59 97.8  1,755,633  
60-69 100.0  1,047,241  
70-79 99.5  1,042,183  






Caregiver costs are the amounts paid to professional caregivers or the 
uncompensated costs that others spend providing care. The replacement cost 
approach was taken so it was assumed that paid and unpaid caregivers’ time had 
the same value. Caregiver costs were taken from the Korea Health Panel (2008) 
and were updated to reflect changes in the consumer price index in 2017. The 
formula for calculating caregiver costs was as follows: 
 
Caregiver costs = average length of stay × Nursing fee per day 
 





Table 20. Caregiver costs 
 
Age 
Average length of 




30-39 5.36  358,092  
40-49 3.06  203,998  
50-59 8.16  544,489  
60-69 12.15  811,427  
70-79 74.59  4,979,543  
≥80 70.19  4,685,989  
Cerebrovascular 
disease 
30-39 43.53  2,906,321  
40-49 102.55  6,846,242  
50-59 99.66  6,653,285  
60-69 100.59  6,715,392  
70-79 123.29  8,231,332  
≥80 168.75  11,266,102  
HF 
30-39 4.22  281,888  
40-49 3.70  246,733  
50-59 9.58  639,441  
60-69 12.72  849,051  
70-79 59.34  3,961,824  
≥80 115.51  7,712,125  
MI 
30-39 4.43  295,665  
40-49 4.42  295,092  
50-59 4.75  316,851  
60-69 6.94  463,362  
70-79 32.61  2,176,937  
≥80 112.13  7,485,801  
CKD 
30-39 124.61  8,319,321  
40-49 104.38  6,968,747  
50-59 96.46  6,439,923  
60-69 109.22  7,291,607  
70-79 155.40  10,374,769  




Input Parameters Summarized  
 
The parameters used in this study are summarized in table 21. 
 
Table 21. Input parameters and sources for the CEA model 
Parameter Data Source 
Incidence, among hypertension patients (age dependent) 
Cerebrovascular disease 0.06 ~ 10.52% The NHIS database 
HF 0.02 ~ 3.05% The NHIS database 
MI 0.02 ~ 0.79% The NHIS database 
CKD 0.02 ~ 1.47% The NHIS database 
   
Mortality, among hypertension patients (age dependent) 
Hypertension 0.01 ~ 0.53% The NHIS database 
Cerebrovascular disease 0.28 ~ 5.69% The NHIS database 
HF 0.00 ~ 5.49% The NHIS database 
MI 0.00 ~ 7.03% The NHIS database 
CKD 0.14 ~ 9.30% The NHIS database 
   
Risk reduction (RR, intervention with medication vs. taking medication only) 
Self-monitoring 0.98002 [17] 
Education 0.99791 [17] 
Reminder service 0.97176 [17] 
   
Intervention costs (KRW) 
Self-monitoring 154,000  
Education 221,474 [61] 





Table 21. Input parameters and sources for the CEA model (Continue) 
Parameter Data Source 
Costs (covered, per person, per 1-year, KRW, age dependent) 
Hypertension 1,199,182 ~ 7,304,975 The NHIS database 
Cerebrovascular disease 14,590,289 ~ 29,179,818 The NHIS database 
HF 3,311,351 ~ 19,230,513 The NHIS database 
MI 9,376,611 ~ 24,172,685 The NHIS database 
CKD 40,984,238 ~ 61,373,332 The NHIS database 
   
Utility (QALY)   
Hypertension 1.00  
Cerebrovascular disease 0.65 [76] 
HF 0.64 [76] 
MI 0.70 [76] 







E. Sensitivity Analysis 
 
There were several assumptions surrounding the variables in the cost-
effectiveness model, so it is unclear how much the results reflect reality. 
Sensitivity analysis confirmed that the model accurately reflected reality and that 
the results were stable and robust. Several methods were used to correct for 
uncertainty. 
A one-way sensitivity analysis was conducted. One-way sensitivity analyses 
examine the relative importance of uncertainty in variables by examining only one 
variable at a time. A tornado analysis was used to examine the effects of multiple 
uncertain variables on the study’s results. 





Table 22. Range of variables in the sensitivity analysis 
Variables Base Min Max Assumption 
Intervention costs 
Self-monitoring 154,000 123,200 184,800 
80%~120% Education 221,474 177,179 265,769 
Reminder service 38,550 30,840 46,260 
 
Risk reduction (RR, intervention with medication vs. taking medication only) 
Self-monitoring 0.98002 0.97145 0.98861 
80%~120% Education 0.99791 0.99295 1.00000 
Reminder service 0.97176 0.95767 0.98606 
 




4. Ethics Statement 
This study was reviewed and approved by the Ethical Review Board at Yonsei 







1. Burden of Disease 
 
(1) Incidence and Mortality of CVD 
 
To calculate the DALY, the incidences of hypertension-related diseases and 
mortality were calculated. Both the incidences and mortality showed a sharp 
increase with age when examining crude rates. The age-standardized incidences of 
CVD in male hypertensive patients totaled 29.77 person-year/1,000 for 
cerebrovascular disease, 6.62 person-year/1,000 for CKD, 6.11 person-year/1,000 
for MI, and 4.86 person-year/1,000 for HF. In contrast, the age-standardized 
incidences of CVD in female hypertensive patients totaled 34.91 person-
year/1,000 for cerebrovascular disease, 8.65 person-year/1,000 for HF, 3.71 
person-year/1,000 for CKD, and 3.08 person-year/1,000 for MI. As indicated, 
both men and women were found to have the highest incidence of cerebrovascular 
disease compared to the other diseases. 
Mortality showed a similar tendency as the incidences. The age-standardized 
mortality of male hypertensive patients was 3.71 person-year/1,000 for 
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cerebrovascular disease, 1.16 person-year/1,000 for CKD, 0.65 person-year/1,000 
for HF, and 0.54 person-year/1,000 for MI. The age-standardized mortality of 
female hypertensive patients was 3.47 person-year/1,000 for cerebrovascular 
disease, 0.74 person-year/1,000 for CKD, 0.65 person-year/1,000 for HF, and 0.41 
person-year/1,000 for MI. Similar to the incidences, both men and women were 









Table 23. Incidence of CVD among hypertensive patients 
(Unit: person-year/1,000) 
 Men Women 
CD† HF MI CKD CD† HF MI CKD 
Crude 
30-39 2.30  0.49  0.65  1.26  2.20  0.65  0.15  0.76  
40-49 6.20  0.84  1.94  1.77  5.47  0.92  0.37  1.02  
50-59 14.37  1.45  3.26  2.61  12.60  1.61  0.75  1.50  
60-69 25.25  2.68  3.96  4.23  21.84  3.33  1.36  2.34  
70-79 48.18  6.56  5.12  7.42  39.75  8.37  2.68  5.12  
80+ 86.41  15.68  6.59  10.90  61.22  19.00  4.77  10.82  
Age-standardized* 29.77  4.86  6.11  6.62  34.91  8.65  3.08  3.71  
†Cerebrovascular disease 





Table 24. Mortality of CVD among hypertensive patients 
(Unit: person-year/1,000) 
 Men Women 
CD† HF MI CKD CD† HF MI CKD 
Crude 
30-39 0.06  0.01  0.01  0.03  0.07  0.01  0.01  0.02  
40-49 0.18  0.02  0.05  0.13  0.12  0.02  0.01  0.06  
50-59 0.55  0.07  0.11  0.35  0.24  0.04  0.02  0.17  
60-69 1.51  0.18  0.26  0.81  0.57  0.12  0.07  0.47  
70-79 6.60  0.99  0.84  2.29  3.06  0.65  0.31  1.51  
80+ 29.45  5.38  2.45  5.76  16.15  5.16  1.45  5.10  
Age-standardized* 3.71  0.65  0.54  1.16  3.47  0.65  0.41  0.74 
†Cerebrovascular disease 





(2) DALYs of CVD 
 
The DALY was calculated according to CVD in the hypertensive patients 
during the follow-up period. The results follow.  
In male hypertensive patients, the DALY of cerebrovascular disease was 
345,613.88 person-year, that of HF was 51,200.68 person-year, that of MI was 
60,054.97 person-year, and that of CKD was 154,978.85 person-year (Table 25). 
In female hypertensive patients, the DALY of cerebrovascular disease was 
275,955.68 person-year, that of HF was 63,844.58 person-year, that of MI was 
28,474.15 person-year, and that of CKD was 106,402.20 person-year(Table 26). 
Compared to other diseases, the DALY of cerebrovascular disease among 
hypertensive patients was the highest in both men and women; in particular, YLLs 








Table 25. YLLs, YLDs, and DALYs of CVD among male hypertensive patients 
(Units: Person-year) 
 
Cerebrovascular disease HF MI CKD 
 
YLL YLD DALY YLL YLD DALY YLL YLD DALY YLL YLD DALY 
Age group 
30-39 6,443.74  1,238.32  7,682.06  1,312.24  395.43  1,707.67  1,117.34  389.53  1,506.87  3,527.78  961.99  4,489.77  
40-49 23,932.97  4,980.47  28,913.44  3,156.14  986.59  4,142.73  6,866.26  1,087.29  7,953.55  16,631.59  1,600.45  18,232.03  
50-59 60,811.94  12,303.41  73,115.35  7,296.72  1,745.87  9,042.60  11,863.60  2,063.12  13,926.71  37,504.75  2,115.55  39,620.30  
60-69 78,978.88  13,262.30  92,241.18  9,818.98  1,698.85  11,517.82  14,918.63  1,652.28  16,570.90  43,625.00  1,850.55  45,475.55  
70-79 97,805.52  9,065.11  106,870.62  15,863.04  1,363.66  17,226.70  14,950.52  830.16  15,780.68  36,777.29  1,236.58  38,013.87  
≥80 34,550.50  2,240.72  36,791.22  7,132.69  430.47  7,563.16  4,153.04  163.21  4,316.25  8,833.47  313.86  9,147.33  





Table 26. YLLs, YLDs, and DALYs of CVD among female hypertensive patients 
(Units: Person-year) 
 
Cerebrovascular disease HF MI CKD 
 
YLL YLD DALY YLL YLD DALY YLL YLD DALY YLL YLD DALY 
Age group 
30-39 3,965.78  631.32  4,597.09  686.74  224.28  911.02  407.43  51.15  458.58  2,295.39  552.90  2,848.29  
40-49 12,797.00  2,995.34  15,792.34  2,185.58  614.10  2,799.69  853.46  164.18  1,017.64  8,543.11  941.02  9,484.12  
50-59 26,550.08  9,223.95  35,774.03  4,047.45  1,377.20  5,424.65  2,379.78  437.62  2,817.40  20,895.28  1,309.06 22,204.34  
60-69 41,649.16  13,029.70  54,678.86  8,227.99  1,970.97  10,198.96  5,358.47  631.31  5,989.78  30,091.18  1,096.48 31,187.66  
70-79 90,335.26  14,012.19  104,347.45  20,919.01  4,176.70  25,095.71  10,555.92  716.18  11,272.10  30,339.72  894.52  31,234.24  
≥80 55,869.06  4,896.85  60,765.91  17,734.88  1,679.67  19,414.56  6,638.46  280.19  6,918.65  9,131.16  312.40  9,443.56  





(3) Comparing to previous study 
 
To confirm the amount of risk related to hypertension, the results of this study 
were compared to the previous studies of Cha (2006)78 and the GBD group 
(2017)79. However, because the studies’ populations and definitions of diseases 
differed, they could not be compared directly. Nevertheless, through the figure 
comparing this study to the previous studies, the risk of CVD associated with 
hypertension can be indirectly determined.  
The DALYs of cerebrovascular disease of this study were high, whereas the 
DALYs of ischemic heart disease in the GBD study were high.  
 
Figure 6. Comparing to previous study  
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2. Cost-Effectiveness Analysis to Control Blood Pressure 
 
(1) Basic Analysis 
 
A cost-effectiveness analysis of the intervention program to control blood 
pressure was performed, and the costs were divided into two types: medical costs 
that were covered only and medical costs at an uncovered rate. 
The analysis using covered-only costs is shown in Table 27. The total cost of 
the medication treatment alone is about 70,112,958 KRW, and the additional cost 
of intervention is 70,454,005 KRW (+self-monitoring), 70,498,435 KRW 
(+reminder service), and 74,306,325 KRW (+education). In the case of 
effectiveness, the QALY of hypertensive patients under medication treatment was 
18.38, and the total QALY for additional interventions was 18.40 (+self-
monitoring), 18.41 (+reminder service), and 18.38 (+education). Based on these 
results, the ICER was calculated to be 12,781,508 KRW, with the lowest ICER 
from the reminder service. Considering the previous studies in Korea, in which 
the willingness to pay is about 10,500,000~36,400,000 KRW in increasing one 
QALYs80, it can be seen that it is an acceptable strategy to provide a reminder 








Table 27. Treatment cost, patient QALY, and ICER per capita  
Alternatives Cost Incr Cost Eff Incr Eff C/E ICER 
Category of 
dominance 
Medication only 70,112,958  0  18.38 0.00 3,814,271  0  undominated 
Medication  
+ Self-monitoring 
70,454,005  341,047  18.40 0.02 3,828,388  16,009,278  ext. dominated 
Medication  
+ Reminder service 
70,498,435  385,478  18.41 0.03 3,828,960  12,781,508  undominated 
Medication  
+ Education 




2) Sensitivity Analysis 
 
A. Change to Payer Perspectives 
 
To confirm the robustness of the model and to exclude uncertainty in the results 
as much as possible, various analyses were performed. We changed the analysis to 
the payer perspective and conducted a cost-effectiveness analysis considering only 
medical costs as input parameters. As with the basic analysis, we divided the 
medical costs, only including covered and uncovered rates. 
The results of the cost-effectiveness analysis using only covered medical costs 
are shown in Table 30. As in the basic analysis, antihypertensive medications and 
the intervention of reminder services were selected as the undominated 
alternatives. A reminder service with antihypertensive medication added a 
medical cost of 426,083 KRW but increased by 0.03 QALYs in effectiveness. 





Figure 8. Results of cost-effectiveness analysis changing costs  
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Table 28. Treatment cost (payer perspective), patient QALY, and ICER per capita  
Alternatives Cost Incr Cost Eff Incr Eff C/E ICER 
Category of 
dominance 
Medication only 40,701,261  0  16.93 0.00 2,403,708  0  undominated 
Medication  
+ Self-monitoring 
41,071,058  369,798  16.95 0.02 2,422,777  19,098,230  ext. dominated 
Medication  
+ Reminder service 
41,127,344  426,083  16.96 0.03 2,424,946  15,546,860  undominated 
Medication  
+ Education 




B. Uncertainly Analysis Related to Discount Rate and CVD Risk 
Reduction 
 
To confirm how the parameters used in the model affect the results, a 
sensitivity analysis was performed using the CVD risk reduction of intervention 
and discount rates for costs and effectiveness. The results are shown in Figures 9 
and 10 and Tables 29 and 30. We found that the net monetary benefits display the 
greatest uncertainty by the discount rate. When the sensitivity analysis was 
performed according to the risk reduction of disease, the net monetary benefits 
changed significantly according to the risk reduction of CVD when the reminder 









Figure 10. Uncertainly analysis related to risk reduction of CVD
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Table 29. Results of uncertainly analysis related to discount rates and risk reduction of CVD 
Variable Name Variable Low 
Variable 
High 
Low High Risk % Cum Risk % 
Discount rate 0.03 0.07 107,247,397  132,111,421  0.999870680 0.999870680 
RR of reminder 
service † 
0.95767 0.98606 122,895,346  123,164,602  0.000117255 0.999987935 
RR of self-
monitoring† 
0.97145 0.98861 122,895,346  122,981,716  0.000012065 1 
RR of education† 0.99295 1.00195 122,895,346  122,895,346  0 1 
†Risk reduction caused by treatment adding to each intervention to treat hypertension patients 
 






Low High Risk % Cum Risk % 
RR of reminder 
service † 
0.95767 0.98606 122,895,346  123,164,602  0.906703914 0.906703914 
RR of self-
monitoring† 
0.97145 0.98861 122,895,346  122,981,716  0.093296086 1 
RR of education† 0.99295 1.00195 122,895,346  122,895,346  0 1 





C. One-way Sensitivity Analysis 
 
A one-way sensitivity analysis was performed by setting 3% and 7% as the 
minimum and maximum values, respectively, at a discount rate of 5%. The results 
are shown in Table 34. Setting the discount rates at 3% and 7%, the ICER was 
10,750,141 KRW (3%) and 20,047,800 KRW (7%) when the reminder service 
was combined with medication treatment, making this the most acceptable 
strategy. In addition, despite the change in the discount rate, education 
intervention is costliest when combined with medication but its effectiveness 





Table 31. Results of one-way sensitivity analysis 
Discount 
rate 




















145,647,324  6,032,073  25.88 0.00 5,626,952  1,172,822,759 (Dominated) 
7% 

















D. Tornado Analysis for Alternative Comparison 
 
A tornado analysis was performed to determine the effect of the ICER using 
the costs incurred in each intervention and the risk reduction in CVD from each 
intervention. Among the alternatives of this study, we identified others when 
adding the reminder service to medication treatment. The results of the remaining 
alternatives are included in the appendix. 
Comparing the medication treatment and additional intervention of reminder 
services, we can see that the CVD risk reduction through using the reminder 
service significantly affects the results, which changes the ICER from 4,560,434 
KRW to 37,967,018 KRW.  
 
Figure 11. Tornado diagram comparing to alternatives 
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Low High Risk % 
Cum 
Risk % 
RR of reminder service 0.95767 0.98606 4,560,434  37,967,018  0.860 0.860 
Cost of reminder service 30,840  46,260  7,906,681  17,656,335  0.073 0.933 
Discount rate 0.03 0.07 10,750,141  20,047,800  0.067 1 
RR of self-monitoring 0.97145 0.98861 12,781,508  12,781,508  0 1 
RR of education 0.99295 1.00195 12,781,508  12,781,508  0 1 
Cost of self-monitoring 24,640  36,960  12,781,508  12,781,508  0 1 






1. Discussion of Study Methods 
 
The purpose of this study was to identify the burden of CVD in hypertensive 
patients in Korea. The incidences and mortality of CVD were calculated using the 
most representative data in Korea, and the DALY was derived by calculating the 
YLL and YLD. Through this, we sought to determine the risk of hypertension in 
Korea. Also, we conducted a cost-effectiveness analysis to determine the most 
acceptable and effective non-pharmaceutical intervention by conducting 
additional interventions presented in the Hypertension Society's guidelines in 
addition to the existing medication treatment to control blood pressure. There are 
some considerations of the study methods. 
In this study, we used 10% sampling data of hypertensive patients from 2007 to 
2017 in Korea to calculate the burden of disease caused by hypertension. The data 
were provided by the NHIS and are the most representative data by sampling 
patients. The subjects of this study were hypertensive patients over 30 years old. 
In general, the risk of chronic disease is known to be more burdensome in older 
patients81. Indeed, this study also showed that the CVD risk increased rapidly 
from the age of 70; it is well known that CVD is the leading cause of death among 
87 
 
elderly people over 60 years old82. For this reason, studies involving chronic 
diseases such as CVD often use the elderly as study subjects. However, because 
chronic diseases are managed from the early stage of their outbreaks, it makes it 
easier to reduce the transition probability of various complications and the 
severity of other diseases83. It is also important to take preventive steps for people 
at a high risk of disease84. Thus, this study aims to suggest preventive methods for 
blood pressure control using adults over 30 years old as subjects. 
This study used the DALY developed by the WHO and GBD studies to 
calculate the burden of disease in hypertensive patients. Because the DALY 
generally represents the burden of disease and disability and the burden of death at 
the national level as a quantified value, it can compare health indicators across 
countries and determine priorities in the commitment of medical resources85. 
Generally, there are two methods for calculating the burden of disease based on 
incidences and prevalence39,41. Both methods suggested by the WHO and GBD 
have advantages and disadvantages. In this study, the prevalence was not available 
because the data used were 10% sampled from all hypertensive patients. Using the 
prevalence-based method has the advantage of using the actual number of patients 
but has the disadvantage that only that current number can be confirmed45. 
However, the incidence-based method can identify trends in disease burden, 
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which may provide more helpful evidence for policymakers who present relevant 
strategies39,41. 
A common method of calculating the burden attributable to a risk factor 
includes determining the relative probability of a risk factor, finding the DALY of 
the disease, and applying the ratio contributed by the risk factor86. Previous 
studies also derive attributable burdens to determine how hypertension contributes 
as a risk factor. In particular, the population attributable fraction (PAF) has the 
advantage of finding the most fundamental cause of disease incidence and death 
and establishing prevention in advance because it can identify the degree of risk 
for the entire population87. In this study, the actual burden of disease was 
calculated by setting the study subjects as hypertensive patients without using the 
PAF. Through this method, we sought to obtain a more accurate actual burden of 
disease. 
To identify the most cost-effective method among the various intervention 
programs that can be used to control the blood pressure of hypertensive patients, 
this study used a cost-effectiveness analysis. A cost-effectiveness analysis is a 
method of evaluating alternatives to make more efficient use of limited 
resources59. It is the most appropriate method to find the best option among two or 
more alternatives, as in this study. In particular, it can be said to be the most 
effective way to predict results through assumptions, rather than actual research. 
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In this study, we selected interventions that are currently being implemented as 
a national program in Korea from the non-pharmaceutical interventions suggested 
by the Hypertension Association's guidelines for blood pressure control12,33. The 
most obvious way to manage high blood pressure is to take antihypertensive 
medication12,15. However, as is well known, chronic diseases such as hypertension 
have a great influence on the lifestyle of the patient, so additional interventions to 
improve this lifestyle will help patients control blood pressure more 
efficiently12,14-16,88. Therefore, we selected interventions in addition to the current 
medication treatment to suggest a better treatment method for hypertensive 
patients even if the cost increases. In addition, we used the probability of reducing 
the CVD risk as the effect of each intervention in this study. Because this 
probability was cited from the results of previous studies that conducted meta-
analyses, we tried to derive more general findings. 
In the cost-effectiveness analysis, we used variables that assess the quality of 
life as effectiveness variables. This was to calculate not only the disease-related 
effects but also the quality of life of the patient to calculate the pain caused by the 
disease89-91. The most commonly used quality of life variables in economic 
evaluations are the QALY and DALY38. The DALY is a tool for evaluating 
disability and mortality due to disease for the entire population, and it is generally 
confirmed by the effect of national infection programs and immunization projects 
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in developing countries92,93. However, because the DALY cannot indicate the 
difference in the quality of life and the effect on individual patients, the QALY is 
used as an indicator to compensate for this shortcoming. The use of the QALY has 
the advantage of showing how the quality of life has changed due to interventions 




2. Discussion of Study Results 
 
This study calculated the burden of CVD in hypertensive patients and identified 
the most cost-effective intervention to be combined with medication treatment for 
blood pressure control. 
As previously mentioned, during the follow-up period, the burden of CVD in 
male hypertensive patients totaled 345,613.88 person-year for cerebrovascular 
disease, 51,200.68 person-year for HF, 60,054.97 person-year for MI, and 
154,978.85 person-year CKD. Female hypertension patients showed similar 
results: the burden of CVD was 275,955.68 person-year for cerebrovascular 
disease, 63,844.58 person-year for HF, 28,474.15 person-year for MI, and 
99,575.16 person-year for CKD. As indicated, both men and women with 
hypertension have the highest burden of cerebrovascular disease compared to 
other diseases. 
The results of this study show that the CVD incidences and mortality of 
hypertensive patients are significantly higher with cerebrovascular disease, which 
is similar to the findings of previous studies and related statistical data. In 
particular, cerebrovascular disease is the second leading cause of death in Korea82. 
Also, its portion of incidences and mortality is likely to be higher in hypertensive 
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patients only. Similarly, this study finds that the burden of CVD of hypertensive 
patients is similar to that of cerebrovascular disease. In a 2006 Korean study78, the 
burden of CVD attributable to hypertension was found to be 385,274 person-years 
and the burden of cerebrovascular disease was 184,222 person-years, which was 
2.1 times higher than the burden of ischemic heart disease. This is expected, but 
the incidences and mortality of cerebrovascular disease are higher than other 
cardiovascular diseases. 
The present results show that the DALYs of CVD were significantly higher 
than those in the previous studies. The burden of disease, which emerged in the 
1990s, has the advantage of being able to be quantified using the DALY as a 
single health indicator94. In addition, the PAF was used to calculate the 
contribution of specific risk factors to the incidence or mortality of a disease 
among the population87,95. All of these methods can be used to measure the burden 
of disease in a nation or population but are unable to calculate the DALYs for a 
particular disease or condition. Therefore, this study attempted to narrow the 
scope of the disease burden measurement by setting the reference population as 
specific patients rather than the general population, unlike the existing burden 
measurement methods. The reference population for this particular disease is 
focused on hypertension; thus, a more accurate DALY can be measured. 
93 
 
In addition, when comparing the YLL and YLD constituting the DALY, YLLs 
due to premature death in all diseases occupy an absolute portion of the DALY, 
which slightly differs from previous studies. In 2001, a study that measured the 
DALY for hypertension-related diseases showed that the YLL was 20,585 person-
years for men and 24,260 person-years for women, and the YLD was 973,365 
person-years for men and 719,021 person-years for women42. However, a study in 
2006 found that the YLL of ischemic heart disease was 147,641 person-years, the 
YLD was 26,931 person-years, the YLL of cerebrovascular disease was 360,121 
person-years, and the YLD was 9,334 person-years78. It can be considered slight 
different, that the definition of hypertension of a study in 2001 was hypertensive 
heart disease (ICD-10: I10-I13) comparing that of this study (ICD-10: I10). 
For hypertensive patients, the most effective way to control blood pressure is to 
take medications12. However, patients may not take their medications unless they 
become habitual or are aware of the importance of taking them. Therefore, if 
hospitals and medical staff give patients reminders about their medications, they 
will become habitual96,97. As such, the treatment of hypertension relies on 
increasing the medication adherence as much as the medication itself98. In a study 
conducted in the United States on Medicaid patients who were reminded to take 
antihypertensive drugs, medication adherence was significantly higher and blood 
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pressure control was greatly improved during the study period99. Thus, to control 
blood pressure, it is necessary to increase medication adherence. The reminder 
service confirmed in this study may be helpful in this role. From these results, it is 
important to consider ways to help patients manage their own blood pressure by 
conducting intervention programs that can help them recognize their habits 
regarding daily blood pressure control. 
Hypertension education is a method used by many institutions to improve the 
understanding of the disease and the lifestyles of hypertensive patients30,83. 
Hypertension education usually includes a description of the disease, how to use a 
sphygmomanometer to help patients recognize and manage their blood pressure 
levels, healthier eating habits to control blood pressure, and a simple exercise that 
patients can do every day100. In Korea, as part of the chronic disease management 
program, such health education is provided by public health centers56. This study 
found that educational program costs are higher than the current blood pressure 
control method but their effectiveness cannot be confirmed. However, other 
previous studies have found that education is cost-effective, but this can vary 
greatly depending on who offers the education and what programs are 
provided101,102. Previous studies have shown that education intervention is cost-
effective when the providers are medical staff, such as physicians or pharmacists, 
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or when case management for patients is included61,103. In this study, education 
was selected as a dominated intervention but it cannot be interpreted as useless. 
Through these findings, policymakers can develop effective educational programs 
for hypertensive patients. However, it will be necessary to develop a 
comprehensive intervention program considering various blood pressure control 
methods. 
It is of note that a study in Argentina conducted a cost-effective analysis of 
interventions that could reduce the CVD burden by dividing population-based 
interventions and clinical interventions13. Except for interventions of medication 
therapy for high-risk CVD groups, the study only evaluated mass media 
campaigns targeting the entire population that were found to reduce smoking by 
7%. As such, it is a viable alternative to consider interventions involving the entire 






This study had some limitations. 
First, this study analyzed 10% of data for all hypertensive patients in South 
Korea, so the sampling method may have introduced a selection bias. In addition, 
this data is secondary data gathering patient information billed to medical 
institutions, even though the actual hypertension or related diseases may be 
present, there may be patients who do not come to the hospital. 
Second, the purpose of this study was to determine the scale of disease burden 
due to hypertension by calculating the burden of CVD in patients with 
hypertension. As previously described, to calculate the attributable burden of 
disease, the DALY of the disease is determined for the entire population and then 
found using the relative risk contributed by each factor. However, in this study, 
patients with hypertension are unable to determine how much the risk factor of 
hypertension accounts for CVD incidence and mortality. 
Third, in this study, the change of systolic blood pressure was considered a 
CVD risk reduction as an effect of the intervention program for blood pressure 
control. This value was derived from the meta-analysis in the previous study17. 
This study attempted to confirm the effect of implementing an intervention 
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program in a large population. However, there is no guarantee that changes in 
systolic blood pressure will reduce the CVD risk of hypertensive patients, and 
because these results are also averaged from several studies, we cannot assure that 
the same results will be obtained in real patients.  
Fourth, the cost-effectiveness analysis included various parameters, including 
the effects of alternatives to the model, transition probability, death rates, and the 
medical costs of disease. In this study, the parameters related to interventions had 
limitations because most parameters were used by the previous study. 
Additionally, the QALY used as the effectiveness variable reflects the quality of 
life of CVD patients as the values quoted in the previous study because the QALY 
cannot be calculated after experiencing the intervention program. As such, there 
are many assumptions in the model structure. 
Despite these limitations, the strengths of this study follow. Because the study 
subjects were hypertensive patients, even when calculating the burden of disease, 
more realistic values could be obtained. Also, by calculating the transition 
probability, death rates, and medical costs used in the cost-effectiveness analysis, 
the effects of the alternatives could be confirmed with more accurate values. 
Finally, this study appears to be the first to have simultaneously compared several 
interventions for controlling blood pressure and to have introduced the most cost-
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This study quantified the burden of CVD among hypertensive patients and 
determined the most cost-effective intervention programs with taking medications 
for controlling blood pressure through a cost-effectiveness analysis. The results 
showed that the burden of cerebrovascular disease was the highest, especially in 
premature death. The reminder service was shown to be the most cost-effective 
intervention program at controlling blood pressure when used in combination with 
medication. 
This study has a great advantage in that it is not possible to confirm similar 
studies in terms of calculating the disease burden of patients with specific diseases 
and conducting the cost-effectiveness analysis of various intervention programs. 
This study’s results can be used as evidence in establishing health-related policies 
for the prevention and management of hypertension and CVD. Especially, 
medical providers should consider developing an intervention to control blood 
pressure that would be less costly and have high effects on patients. Although this 
study was the first of its kind, its results must be carefully interpreted due to its 
limitations. Further research should be conducted to overcome this study’s 
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Appendix 1. Baseline characteristics of study population calculating DALY 
 Men Women 
P 
N/means %/SD N/means %/SD 
Total 635,141  49.1% 658,035  50.9%  
      
Age group      
30-39 71,796  11.3% 39,677  6.2% 
<.0001 
40-49 146,917  23.1% 112,676  17.7% 
50-59 173,163  27.3% 160,693  25.3% 
60-69 138,594  21.8% 159,376  25.1% 
70-79 82,164  12.9% 130,045  20.5% 
>80 22,507  3.5% 55,568  8.7% 
     
 
Income level     
 
20% 101,581  16.0% 136,323  21.5% 
<.0001 
40% 100,149  15.8% 103,043  16.2% 
60% 111,764  17.6% 105,027  16.5% 
80% 140,531  22.1% 134,918  21.2% 
100% 181,116  28.5% 178,724  28.1% 
     
 
Smoking status     
 
Former 32,468  5.1% 1,378  0.2% 
<.0001 
Current 67,228  10.6% 3,718  0.6% 
No smoking 83,215  13.1% 139,031  21.9% 
N/A 452,230  71.2% 513,908  80.9% 
     
 
SBP 131.30 15.70 129.62 16.84 <.0001 
DBP 81.96 10.53 79.51 10.54 <.0001 
BMI 24.74 3.01 24.53 3.26 <.0001 





Appendix 2. Number of incidence and mortality of CVD among male hypertensive patients 
(Unit: person) 
 Incidence Mortality 
CD† HF MI CKD CD† HF MI CKD 
30-39 1,471  316  422  808  38  9  8  22  
40-49 8,026  1,109  2,551  2,324  238  31  67  170  
50-59 21,172  2,239  5,011  4,015  810  106  165  545  
60-69 28,324  3,278  4,848  5,145  1,699  219  324  988  
70-79 28,678  4,659  3,691  5,238  3,927  701  607  1,618  
80+ 11,333  2,870  1,282  2,036  3,863  984  476  1,077  





Appendix 3. Number of incidence and mortality of CVD among female hypertensive patients 
(Unit: person) 
 Incidence Mortality 
CD† HF MI CKD CD† HF MI CKD 
30-39 779  233  54  487  24  4  2  16  
40-49 5,454  930  379  1,340  120  21  9  82  
50-59 17,463  2,312  1,084  2,316  336  53  31  269  
60-69 28,903  4,703  1,940  2,876  753  165  95  579  
70-79 39,394  9,385  3,095  3,665  3,030  725  353  1,081  
80+ 22,548  8,497  2,329  2,033  5,948  2,305  709  959  





Appendix 4. The markov model in this study 
 
* Every Markov node added identical tree structure 
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Appendix 6. Results of tornado analysis comparing to alternatives (medication only vs. medication + self-
monitoring) 
Variable Name Variable Low Variable High Low High Risk % Cum Risk % 
RR of self-monitoring 0.97145 0.98861 7,667,436  36,901,866  0.757 0.757 
Discount rate 0.03 0.07 12,771,745  25,140,740  0.135 0.892 
Cost of self-monitoring 24,640  36,960  10,497,187  21,521,369  0.108 1 
RR of education 0.99295 1.00195 16,009,278  16,009,278  0 1 
RR of reminder service 0.95767 0.98606 16,009,278  16,009,278  0 1 
Cost of education 177,179  265,768  16,009,278  16,009,278  0 1 






Appendix 7. Results of tornado analysis comparing to alternatives (medication only vs. medication + 
education) 
Variable Name Variable Low Variable High Low High 
Discount rate 0.03 0.07 1,172,822,759  2,999,332,044  
Cost of education 177,179  265,768  1,508,393,324  2,268,317,161  
RR of self-monitoring 0.97145 0.98861 1,888,359,532  1,888,359,532  
RR of reminder service 0.95767 0.98606 1,888,359,532  1,888,359,532  
Cost of self-monitoring 24,640  36,960  1,888,359,532  1,888,359,532  
Cost of reminder service 30,840  46,260  1,888,359,532  1,888,359,532  








고혈압으로 인한 질병 부담과 혈압 조절을 위한 비약물적 
중재프로그램의 비용효과분석 
 
연세대학교 일반대학원 보건학과 
이예슬 
 
서론: 고혈압은 한국뿐만 아니라 전세계적으로 가장 흔한 만성질환 중 
하나이다. 한국의 고혈압 유병 인구는 꾸준히 증가하고 있으며, 관련 의료비 
지출 또한 증가하고 있다. 고혈압은 단일상병으로도 문제가 있지만 많은 
만성질환의 가장 큰 위험요소로 그 문제가 더 크다. 하지만 반대로 고혈압을 
적절히 관리하면 심뇌혈관질환 발생 위험이 낮으며, 관련 합병증 발생 또한 
낮은 것을 확인할 수 있다. 국내외로 고혈압을 조절하기 위한 중재프로그램은 
다양하게 존재하고 있는데, 이러한 중재프로그램은 환자들에게 고혈압에 대한 
인지율, 조절율 및 치료율을 높임으로써 더 효과적인 고혈압 치료를 도와주는 
역할을 수행한다. 하지만 여러 중재프로그램을 비교하여 고혈압 
예방차원에서의 비용효과를 확인한 연구는 전무하다고 볼 수 있어 이에 대한 
연구가 필요하다. 이에 본 연구는 한국에서 고혈압의 질병 부담이 어느 
정도인지 확인함으로써 고혈압에 대한 인식을 높이고 혈압 조절을 위한 
중재프로그램을 진행하는데 있어 어떠한 중재프로그램이 비용효과적인지 




연구방법: 이 연구는 건강보험공단 의료정보데이터와 생명표 등을 활용하여 
분석하였다. 연구대상은 30 세 이상 고혈압 환자(I10)로 설정하였으며, 
심뇌혈관질환은 뇌혈관질환(I60-69), 심부전(I50), 심근경색(I21-24), 
만성신장질환(N18)으로 정의하였다. 고혈압 환자들의 질병 부담을 산출하기 
위하여 다음과 같은 순서로 진행하였다. 고혈압 환자들의 심뇌혈관 질환의 
발생 및 사망률을 산출하였다. 이를 바탕으로 심뇌혈관질환의 YLL, YLD, 
DALY 를 산출하였다. 이 때 발생률 기반 산출방식을 채택하였다. 혈압 조절을 
위한 중재프로그램의 비용효과분석을 하기 위하여 마콥모형을 이용하였다. 
중재프로그램의 정의와 효과는 선행연구를 인용하여 설정하였고, 종류로는 
비약물적 요법으로써 자가 관리, 교육, 리마인더 서비스로 채택하였다. 가장 
비용효과적인 대안을 선택하였고, 분석 관점은 제한적 사회적 관점으로 
설정하였다. 1 년의 분석 주기와 평생으로 분석 기간을 설정하였고 
효과변수로는 QALY 를 이용하였다. 비용에는 각 중재프로그램의 예산과 
고혈압 및 관련 질병의 의료비, 비의료비용을 포함하였다.  
 
결과: 고혈압 환자들을 대상으로 심뇌혈관질환의 발생과 사망률은 
연령표준화비율로 뇌혈관질환에서 가장 높은 것을 보였다 (남성: 
29.77 인년/1,000 명(발생), 3.71 인년/1,000 명(사망); 여성: 
34.91 인년/1,000 명(발생), 3.47 인년/1,000 명(사망)). 고혈압 환자들의 
심뇌혈관질환 DALY 로는 남녀 모두 뇌혈관질환이 가장 높았다. (남성: 
뇌혈관질환 221,938.98 인년, HF 37,127.45 인년, MI 41,197.93 인년, CKD 
114,429.18 인년; 여성: 뇌혈관질환 186,096.67 인년, HF 40,521,86 인년, MI 
17,882.92 인년, CKD 99,575.16 인년) 특히 질병부담에 있어 조기사망으로 
인한 YLL 이 DALY 에서 절대적인 부분을 차지하였다. 혈압 조절을 위한 
중재프로그램의 비용효과분석에서는 기존의 약물요법과 함께 리마인더 
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서비스를 시행했을 때의 ICER 값은 12,781,508 원으로 나타났다. 이는 여러 
가지 불확실성평가를 시행하였음에도 비슷한 결과를 가져왔다.  
 
결론: 본 연구를 통해서 고혈압 환자들의 심혈관질환의 부담이 높았으며, 
특히, 조기사망으로 인한 부담이 현저하게 높았다. 고혈압 환자들을 대상으로 
혈압 조절을 위해 약물치료와 함께 리마인더 서비스를 추가로 진행할 경우 
비용효과적 관점에서 선택할 수 있는 대안으로 선정되었다. 이는 고혈압 
환자들에게 추가적으로 리마인더 서비스를 시행하면 비용을 좀 더 
지불하더라도 효과가 그 이상으로 높기 때문에 중재프로그램을 도입하기에 
충분히 가능하다고 해석할 수 있다. 이 연구는 특정 질환자의 질병부담을 
산출하고 혈압 조절을 위한 여러 중재프로그램의 비용효과성을 비교했다는 
점에서 동일한 연구를 확인할 수 없음에 큰 장점을 가지고 있으며, 고혈압 및 
심뇌혈관질환 예방 관리에 있어서 관련 정책을 수립할 때 도움을 줄 수 있는 
근거자료로 활용할 수 있을 것이다. 그럼에도 불구하고 연구 제한점이 있기 
때문에 그 해석에 있어 조심할 필요가 있으며, 제한점을 극복하기 위한 
후속연구가 더 필요할 것이다.  
                                                                   
핵심어: 고혈압, 심뇌혈관질환, 질병부담, DALY, 혈압조절관리, 비용효과분석, 
리마인더 서비스, 혈압자가관리, 고혈압 교육 
